跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT05160051
NCT05160051已完成2 期

68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer: A Single-center Prospective Interventional Single-arm Clinical Trial

University Hospital, Essen2 个研究点 分布在 1 个国家目标入组 158 人开始时间: 2021年12月1日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
158
试验地点
2
主要终点
Positive predictive value (PPV) on a per-region- and per-patient-basis (table 3) of 68Ga-FAPI46 PET for detection of histopathology-FAP-positive tumor lesions, confirmed by histopathology/biopsy (reached for ≥ 75%).
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is to explore the safety and tolerability as well as diagnostic accuracy of 68Ga-FAPI-46 for different FAP-expressing tumor entities by PET.

This study does not offer any treatment for patients with FAP-expressing carcinomas; therefore, patients will be offered state of the art therapeutic options. Routine surgery will be performed within 8 weeks after 68Ga-FAPI-46 PET.

详细描述

Primary Endpoint:

Positive predictive value (PPV) on a per-region- and per-patient-basis of 68Ga-FAPI-46 PET for detection of histopathology-FAPpositive tumor lesions, confirmed by histopathology/biopsy (reached for ≥ 75%).

Secondary Endpoints:

  1. Association between 68Ga-FAPI-46 PET uptake intensity and histopathologic FAP expression
  2. Sensitivity and specificity of 68Ga-FAPI-46 PET on a per-patient and per-region-basis for detection of histopathology-FAPpositive tumor lesions confirmed by histopathology/biopsy (separate for regional, extra-regional and distant locations)
  3. Detection rate of 68Ga-FAPI-46 PET versus previous standard imaging on a per-patient and per-region-basis for detection of tumor location, also stratified by tumor maker serum level
  4. Sensitivity and specificity of 68Ga-FAPI-46 PET versus previous standard imaging on a per-patient and per-region-basis for detection of tumor lesions confirmed by combined histopathology/biopsy/follow-up imaging/clinical follow-up reference standard (separate for regional, extra-regional and distant locations)
  5. Impact on management
  6. Inter-reader reproducibility
  7. Safety
  8. Change in staging/prognostic groups

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Proven or suspected tumor types: Breast, Colorectal, Endometrial, Esophageal, Glioma/GMB, Head and neck, Hepatocellular carcinoma, ,Lymphoma, Multiple Myeloma, Neuroendocrine, NSCLC (Non small cell lung cancer), Ovarian, Pancreatic, Prostate, Renal cell carcinoma, Sarcoma, SCLC (Small cell lung cancer), Semimoma, Thyroid, Unknown primary, Other
  • •At initial staging or re-staging of disease
  • •At least one detectable tumor lesion with any diameter >1 cm
  • •Intended or performed surgery or biopsy of tumor within 8 weeks before or after enrollment
  • •Age ≥18 years
  • •Patient Eastern Cooperative Oncology Group (ECOG) performance status ≤
  • •Women of child bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, can only be included after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test within 24 h before radiopharmaceutical application.

排除标准

  • •Patient cannot give consent for the study
  • •Patient cannot lie flat or tolerate 68Ga-FAPI-46 PET imaging
  • •Prior external beam radiation therapy (EBRT) within 3 months of enrollment to tumor lesions intended for surgery or biopsy
  • •Prior chemotherapy, immunotherapy, biologic or targeted oncologic therapy within 3 months of enrollment
  • •Unwillingness or inability to comply with study and follow-up procedures
  • •History of disease or condition that may critically interfere with participation in this study at the discretion of the investigators
  • •Pregnant, lactating, or breast-feeding women
  • •Women of child bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, are not allowed to participate in this study, unless they are using highly effective methods of contraception during the interventional period. Highly effective contraception methods include:
  • •True sexual abstinence: defined as refraining from heterosexual intercourse, when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence for the duration of exposure to IMP, and withdrawal are not acceptable methods of contraception.
  • •Vasectomised partner is a highly effective birth control method if the partner is the sole sexual partner of the study participant and the vasectomised partner has received medical assessment of the surgical success.
  • •Bilateral tubal occlusion.
  • •Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation:
  • •intravaginal
  • •transdermal
  • •Progestogen-only hormonal contraception associated with inhibition of ovulation:
  • •injectable
  • •implantable
  • •Placement of an intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
  • •Post-menopausal women are allowed to participate in this study. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms), or six months of spontaneous amenorrhea with serum folliclestimulating hormone (FSH) levels > 40mIU/mL or have had surgical bilateral oophorectomy or bilateral salpingectomy or hysterectomy or tubal ligation at least six weeks prior to screening. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
  • •Sexually active males must use a condom during intercourse during the interventional period. A condom is required to be used also by vasectomized men in order to prevent delivery of the study compound via seminal fluid
  • •QTcF >470 msec for females and QTcF >450 msec for males on screening electrocardiogram (ECG) or history of congenital long QT syndrome.
  • •Known or expected hypersensitivity to 68Ga-68-FAPI-46 or any of the relevant excipients.

结局指标

主要结局

Positive predictive value (PPV) on a per-region- and per-patient-basis (table 3) of 68Ga-FAPI46 PET for detection of histopathology-FAP-positive tumor lesions, confirmed by histopathology/biopsy (reached for ≥ 75%).

时间窗: within 8 weeks of FAPI-PET scan, when a tumor sample becomes available for immonostaining for FAP

次要结局

  • Sensitivity and specificity of FAPI-PET on a per-patient and per-region-basis for detection of histopathology-FAP-positive tumor lesions confirmed by histopathology/biopsy(within 8 weeks of FAPI-PET scan, when a tumor sample becomes available for immonostaining for FAP)
  • Correlation between 68Ga-FAPI-46 PET uptake intensity and histopathologic FAP expression(within 8 weeks of FAPI-PET scan, when a tumor sample becomes available for immonostaining for FAP)
  • Change in staging/prognostic groups per survey of referring physician who was provided with FAPI-PET scan information.(through study completion, an average of 1 year)
  • Detection rate of FAPI-PET versus previous standard imaging on a per-patient and per-region-basis for detection of tumor location, also stratified by tumor maker serum level(up to time point when patient reaches end-of-study criterion (30day, if surgery is performed within 30 days after FAPI-PET or up to 8 weeks, at time of surgery/biopsy))
  • Inter-reader reproducibility: determination of FAPI-PET scan interpretation reliability by three independent evaluators(through study completion, an average of 1 year)
  • Sensitivity and specificity of FAPI-PET vs. previous standard imaging on a per-patient and per-region-basis for detection of tumor lesions confirmed by combined histo/biopsy/FU imaging/clinical FU reference standard(up to time point when patient reaches end-of-study criterion (30 day, if surgery is performed within 30 days after FAPI-PET or up to 8 weeks, at time of surgery/biopsy))
  • Safety (AEs, SAEs, SUSARs)(From signing the ICF until day 30 after FAPI-PET scan)

研究者

发起方
University Hospital, Essen
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

进行中（未招募）
1 期
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various CancersCervical CarcinomaHematopoietic and Lymphoid Cell NeoplasmMalignant Adrenal Gland NeoplasmMalignant Brain NeoplasmMalignant Pleural NeoplasmMalignant Skin NeoplasmMalignant Solid NeoplasmMalignant Testicular NeoplasmMalignant Thymus NeoplasmThyroid Gland CarcinomaUrothelial CarcinomaCancer of Unknown Primary SiteNeuroendocrine NeoplasmHepatocellular CarcinomaCholangiocarcinomaBladder Carcinoma
NCT04459273Jonsson Comprehensive Cancer Center26
进行中（未招募）
1 期
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology ValidationMetastatic Malignant Neoplasm in the Prostate GlandProstate CarcinomaRecurrent Prostate Carcinoma
NCT04457232Jonsson Comprehensive Cancer Center30
进行中（未招募）
1 期
68Ga-FAPI-46 PET for imaging of FAP expressing cancer: A single-center prospective interventional single-arm clinical Trial
EUCTR2021-000148-23-DEniversity Hospital Essen155
招募中
不适用
FAPI PET/CT in Various FAP-Related Disease PatientsFAP-related DiseasePositron Emission TomographyMetastasisTumor
NCT06688071Tianjin Medical University500
进行中（未招募）
1 期
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With SarcomaMetastatic SarcomaRecurrent SarcomaSarcoma
NCT04457258Jonsson Comprehensive Cancer Center18